BioAmicus Complete for Functional Gastrointestinal Symptoms in Infants Aged 0 to 24 Months

Официальное название

Evaluation of the Efficacy and Safety of the Multistrain Probiotic "BioAmicus Complete" in Improving Gastrointestinal Symptoms in Children Aged 0-24 Months: A Randomized, Open-Label, Parallel-Group, Controlled Trial

Обзор

Infants often experience functional gastrointestinal symptoms (e.g., colic, excessive gas, regurgitation, constipation, or loose stools) that distress families and may reflect an imbalance of the gut microbiome. This study evaluates whether the multistrain probiotic BioAmicus Complete can improve caregiver-reported gastrointestinal symptoms in infants 0-24 months and is safe for use in this population. The primary assessment is the change in the Infant Gastrointestinal Symptom Questionnaire (IGSQ) total score from the start to the end of the study period. Secondary assessments include symptom domains (colic/regurgitation, stool frequency and consistency), caregiver quality of life, growth parameters (weight and length), health care utilization and antibiotic exposure, and overall safety/tolerability (adverse events and serious adverse events). Stool samples will be analyzed to explore changes in the gut microbiome.

Подробное описание

caregiver burden and health care visits. Modulating the developing gut microbiome with probiotics may alleviate these symptoms. BioAmicus Complete is a multistrain probiotic designed to support a healthy intestinal microbiota; systematic clinical evaluation is warranted to determine its efficacy and safety in infants.

Objectives:

Primary: Determine whether BioAmicus Complete improves overall gastrointestinal symptoms versus usual care, measured by change in IGSQ total score between baseline and study end.

Exploratory (microbiome): Characterize changes in stool microbiome composition and diversity across the study period.

Secondary: Compare groups on symptom domain scores (e.g., colic, regurgitation, stooling patterns), caregiver burden/quality of life, health care utilization and antibiotic exposure, growth parameters, and safety outcomes (adverse events, serious adverse events, and product-related events).

Significance: Findings will inform whether BioAmicus Complete can be recommended as an adjunct to routine care for infant functional gastrointestinal symptoms and will provide preliminary insights into microbiome changes associated with symptom improvement.

Вмешательства

• Пищевая добавка BioAmicus Complete
  Oral liquid probiotic (multistrain) administered by caregivers per protocol/label for 42 days to infants with functional GI symptoms. Given as drops by mouth; dosing and administration instructions per protocol. No other probiotic products allowed during the study. Concomitant medications and routine management may be used as clinically indicated. Adherence is recorded; lot/batch number captured.
• Другое Usual Care (No Probiotic)
  Standard clinical management for infant functional gastrointestinal symptoms per local practice. No probiotic supplementation is provided during the study period. Participants follow the same visit and assessment schedule as the intervention arm. Concomitant medications and supportive care may be used as clinically indicated.

Первичные конечные точки

• Change from Baseline in Infant Gastrointestinal Symptom Questionnaire (IGSQ) Total Score at Day 42 [Срок оценки: Baseline to Day 42]
• Stool Microbiome - Change in Alpha Diversity (Shannon, Chao1) [Срок оценки: Baseline to Day 42]

Вторичные конечные точки (5)

• Change in Stool Frequency Based on Infant & Toddler GI Symptom Questionnaire from Baseline to Day 42 [Срок оценки: Baseline to Day 42]
• Change in Stool Consistency Using the Brussels Infant and Toddler Stool Scale (BITSS) from Baseline to Day 42 [Срок оценки: Up to Day 42]
• Stool Microbiome - Between-Group Difference in Beta Diversity (PERMANOVA) [Срок оценки: Day 42]
• Change in Frequency of Regurgitation and Vomiting Episodes from Baseline to Day 42 [Срок оценки: Baseline to Day 42]
• Change in Colic Symptoms Based on Infant & Toddler GI Symptom Questionnaire from Baseline to Day 42 [Срок оценки: Baseline to Day 42]

Критерии участия

Критерии включения

• Age 0-24 months at enrollment.
• Infant has clinician-assessed functional gastrointestinal symptoms (e.g., colic/irritability, regurgitation, constipation, loose stools), judged suitable for study participation.
• Parent or legal guardian provides written informed consent and agrees to comply with study procedures (questionnaires/diaries and sample collection, if applicable).
• Caregivers agree to avoid other probiotic products during the study period, except as directed by the study team.

Критерии исключения

• Major congenital gastrointestinal anomalies or known chronic gastrointestinal diseases requiring ongoing prescription therapy (e.g., Hirschsprung disease, inflammatory bowel disease, short-bowel syndrome).
• Clinically unstable condition or severe/critical illness that could interfere with participation or safety in the opinion of the investigator.
• Known or suspected primary or secondary immunodeficiency, or current immunosuppressive therapy.
• History of severe allergy or hypersensitivity to components of the investigational product.
• Recent use of systemic antibiotics within 14 days prior to baseline, or use of probiotic supplements within 14 days prior to baseline (per protocol).
• Participation in another interventional clinical trial within 30 days prior to enrollment or during the study.
• Any condition that, in the investigator's judgment, would make the participant unsuitable for the study or confound outcome assessments.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Поддерживающая терапия

Центры проведения

Вьетнам · 1 центр

• Clinical Trial and Bioequivalence Center — Haiphong

Идентификаторы

NCT: NCT07148583 · CTBE.25.03 · Protocol No.: CTBE.25.03

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗